Asthma
| ANDHI study - Astra-Zeneca (52 week)
Principle Investigator: |
Double-blind placebo controlled study to assess the efficacy and safety of Benralizumab (anti-eosinophilic injection) in patients with uncontrolled asthma who have eosinophils >150 cells/ microliter (0.15). Non-smokers (<10 pack-years) 2 exacerbations, FEV1 pre BD <80% |
| LUSTER study - Novartis – Fevipiprant – Th2- antagonist – anti-eosinophilic tablet – 52 weeks with extension into the Spirit study
Principle Investigator: |
Double-blind placebo-controlled, eosinophils >250 cells/microliter (0.25), 2 exacerbations, FEV1 |
| SPIRIT- Novartis - Fevipiprant – Th2- antagonist – anti-eosinophilic tablet up to 3 years
Principle Investigator: |
Double-blind placebo-controlled, pre BD FEV1 |
COPD
| PEARL – Astra-Zeneca
Principle Investigator: |
Double blind- placebo controlled trial. A further development of the Symbicort inhaler and must have had 2 exacerbations with Pred, smokers, >20 pack- years, 52 weeks. |
Bronchiectasis
|
Comng soon. |
